Excellus BCBS

Does Excellus BCBS cover Wegovy?

Quick answer · Weight Loss

Excellus BCBS covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 40 or higher
  • ACA Marketplace: Covered with requirements. BMI of 40 or higher

Last verified June 5, 2026. Source: weight-management-policy-pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What Excellus BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 40 or higher
  • BMI of 35 or higher with a weight-related condition (CVD, dyslipidemia, gallstones, gynecological_abnormalities, hypercholesterolemia, HTN, metabolic_syndrome, MAFLD, pulmonary_hypoventilation, OSA, stress_incontinence, T2DM, and weight_bearing_joint_arthropathy)
  • BMI of 25 or higher for patients of Asian descent
  • BMI at or above the 95th percentile for age and sex
  • 3 months of a documented diet and exercise program
  • Prior trial of another GLP-1 medication (Foundayo) for at least 180 days

Qualification pathways

You can qualify through any one of these.

Adult weight loss — Class III obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 40 kg/m² (Class III obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Adult weight loss — Class II obesity with comorbidity

All of:

  • Age ≥ 18 years
  • BMI 35–39.9 kg/m² (Class II obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Plus any one of:

  • Cardiovascular Disease
  • Dyslipidemia (high LDL, TG, or low HDL)
  • Gallstones
  • Gynecological abnormalities
  • Hypercholesterolemia
  • Hypertension
  • Metabolic Syndrome
  • MAFLD
  • Pulmonary Hypoventilation
  • Obstructive Sleep Apnea
  • Stress Incontinence
  • Type 2 Diabetes
  • Weight-Bearing Joint Arthropathy

Adolescent weight loss (ages 12–17)

All of:

  • Age 12–17 years
  • BMI ≥ 95th percentile standardized for age and sex
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Wegovy tablets and Wegovy HD 7.2mg injection NOT approved for adolescents
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist

Documentation to bring

  • Baseline BMI and weight documentation
  • Height documentation
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)
  • For adolescents: BMI percentile ≥95th for age and sex documentation

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg (Wegovy HD) — 4 pens per 28 days; requests outside this limit not approved; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; first 3 fills of Wegovy HD 7.2mg limited to 28-day supply or less (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days; first 6 fills for new starts limited to 30-day supply or less (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). Continued comprehensive weight management program enrollment required (provider acknowledgement via PA form or progress note). Wegovy HD 7.2mg only for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Non-FDA approved diagnoses not covered
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
  • Ozempic (semaglutide) will not be authorized at doses >2mg once weekly (active weight management formulation Wegovy exists)
  • Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: BMI thresholds may be adjusted for ethnicity on a case-by-case basis; Asian population: BMI ≥25 kg/m² suggests clinical obesity and consideration for pharmacological treatment. Documentation must reflect patient's clinical status at time drug was originally initiated, regardless of date of current coverage request. Patients not treated in past 4 months considered new to therapy. Wegovy HD 7.2mg only indicated for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss. 0.25mg, 0.5mg, and 1mg injection and 1.5mg, 4mg, 9mg tablet dosages are initiation/escalation doses only, not approved as maintenance. Annual day-supply limits apply cumulatively across all GLP-1/GIP-GLP-1 products.

verified June 5, 2026 · source: weight-management-policy-pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 40 or higher
  • BMI of 35 or higher with a weight-related condition (CVD, dyslipidemia, gallstones, gynecological_abnormalities, hypercholesterolemia, HTN, metabolic_syndrome, MAFLD, pulmonary_hypoventilation, OSA, stress_incontinence, T2DM, and weight_bearing_joint_arthropathy)
  • BMI of 25 or higher for patients of Asian descent
  • BMI at or above the 95th percentile for age and sex
  • 3 months of a documented diet and exercise program
  • Prior trial of another GLP-1 medication (Foundayo) for at least 180 days

Qualification pathways

You can qualify through any one of these.

Adult weight loss — Class III obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 40 kg/m² (Class III obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Adult weight loss — Class II obesity with comorbidity

All of:

  • Age ≥ 18 years
  • BMI 35–39.9 kg/m² (Class II obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Plus any one of:

  • Cardiovascular Disease
  • Dyslipidemia (high LDL, TG, or low HDL)
  • Gallstones
  • Gynecological abnormalities
  • Hypercholesterolemia
  • Hypertension
  • Metabolic Syndrome
  • MAFLD
  • Pulmonary Hypoventilation
  • Obstructive Sleep Apnea
  • Stress Incontinence
  • Type 2 Diabetes
  • Weight-Bearing Joint Arthropathy

Adolescent weight loss (ages 12–17)

All of:

  • Age 12–17 years
  • BMI ≥ 95th percentile standardized for age and sex
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Wegovy tablets and Wegovy HD 7.2mg injection NOT approved for adolescents
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist

Documentation to bring

  • Baseline BMI and weight documentation
  • Height documentation
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)
  • For adolescents: BMI percentile ≥95th for age and sex documentation

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg (Wegovy HD) — 4 pens per 28 days; requests outside this limit not approved; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; first 3 fills of Wegovy HD 7.2mg limited to 28-day supply or less (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days; first 6 fills for new starts limited to 30-day supply or less (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). Continued comprehensive weight management program enrollment required (provider acknowledgement via PA form or progress note). Wegovy HD 7.2mg only for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Non-FDA approved diagnoses not covered
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
  • Ozempic (semaglutide) will not be authorized at doses >2mg once weekly (active weight management formulation Wegovy exists)
  • Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: BMI thresholds may be adjusted for ethnicity on a case-by-case basis; Asian population: BMI ≥25 kg/m² suggests clinical obesity and consideration for pharmacological treatment. Documentation must reflect patient's clinical status at time drug was originally initiated, regardless of date of current coverage request. Patients not treated in past 4 months considered new to therapy. Wegovy HD 7.2mg only indicated for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss. 0.25mg, 0.5mg, and 1mg injection and 1.5mg, 4mg, 9mg tablet dosages are initiation/escalation doses only, not approved as maintenance. Annual day-supply limits apply cumulatively across all GLP-1/GIP-GLP-1 products.

verified June 5, 2026 · source: weight-management-policy-pdf

Wegovy for Heart Disease Risk Reduction

What Excellus BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 27 or higher
  • BMI of 25 or higher for patients of Asian descent
  • Prescribed by or in consultation with a specialist
  • Established cardiovascular disease (prior_MI, prior_stroke, symptomatic_PAD_with_ABI_less_than_0.85, prior_peripheral_arterial_revascularization, and amputation_due_to_atherosclerotic_disease)
  • On guideline-directed medical therapy (lipid_lowering_therapy, blood_pressure_lowering_therapy, SGLT2i, and antiplatelet_therapy)
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease without diabetes

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m²
  • Wegovy prescribed by or in consultation with a cardiologist or neurologist (prescriber attestation required)
  • Established cardiovascular disease (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease) documented via progress notes
  • Currently a non-smoker (not smoked in past 6 months)
  • Partaking in a heart healthy diet
  • Engaging in physical activity at level of ability
  • Commitment to continue lifestyle modifications while on Wegovy
  • Optimized on standard of care treatment for prevention of secondary cardiovascular events per prescriber (may include lipid-lowering, blood pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
  • No diagnosis of diabetes mellitus
  • No diagnosis of end-stage renal disease
  • No NYHA Class IV heart failure symptoms
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with any weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

  • Baseline BMI documentation (≥27 kg/m²)
  • Progress notes demonstrating established CVD (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease)
  • Prescriber attestation that Wegovy is prescribed by or in consultation with a cardiologist or neurologist
  • Documentation that patient is currently a non-smoker (not smoked in past 6 months)
  • Documentation that patient is partaking in a heart healthy diet
  • Documentation that patient is engaging in physical activity at their level of ability
  • Documentation of patient commitment to continue lifestyle modifications while on Wegovy
  • Documentation that patient is optimized on standard of care for secondary CVD prevention (lipid-lowering, blood-pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
  • Documentation that patient has no diagnosis of diabetes mellitus, ESRD, or NYHA Class IV heart failure
  • At recertification: documentation of ≥80% PDC since last approval
  • At recertification: documentation of continued non-smoker status, heart-healthy diet, and physical activity

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg — 4 pens per 28 days (Wegovy HD 7.2mg NOT approved for CV risk reduction indication); Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for Upon recertification: patient must be utilizing 2.4mg OR 1.7mg injection OR 25mg tablet as maintenance dose; must demonstrate ≥80% PDC (Percent Days Covered) since last approval; must still be a non-smoker, partaking in a heart healthy diet and engaging in physical activity; must not have developed type 2 diabetes, ESRD, or NYHA Class IV heart failure symptoms. Note: GDMT optimization and CVD diagnosis are not explicitly re-verified at continuation per policy text, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Diabetes mellitus diagnosis excludes from this indication (consider GLP-1 agonists FDA-approved for CV risk reduction in T2DM instead)
  • End-stage renal disease diagnosis excludes from this indication
  • NYHA Class IV heart failure symptoms exclude from this indication
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any weight loss drugs (Rx, OTC, or herbal) not approved
  • Wegovy HD 7.2mg not approved for this indication

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: Standards of care for secondary CVD prevention may include lipid-lowering therapies, blood pressure-lowering therapy, SGLT2 inhibitors when appropriate, and antiplatelet therapy when appropriate — prescriber determines optimization. Wegovy HD 7.2mg explicitly NOT approved for this indication. For patients with type 2 diabetes seeking CV risk reduction, policy directs to GLP-1 agonists FDA-approved for MACE reduction in T2DM. BMI thresholds may be adjusted for Asian population (≥25 kg/m² suggests clinical obesity) on case-by-case basis. Annual GLP-1 day-supply limits apply cumulatively across all products.

verified June 5, 2026 · source: weight-management-policy-pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 27 or higher
  • BMI of 25 or higher for patients of Asian descent
  • Prescribed by or in consultation with a specialist
  • Established cardiovascular disease (prior_MI, prior_stroke, symptomatic_PAD_with_ABI_less_than_0.85, prior_peripheral_arterial_revascularization, and amputation_due_to_atherosclerotic_disease)
  • On guideline-directed medical therapy (lipid_lowering_therapy, blood_pressure_lowering_therapy, SGLT2i, and antiplatelet_therapy)
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease without diabetes

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m²
  • Wegovy prescribed by or in consultation with a cardiologist or neurologist (prescriber attestation required)
  • Established cardiovascular disease (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease) documented via progress notes
  • Currently a non-smoker (not smoked in past 6 months)
  • Partaking in a heart healthy diet
  • Engaging in physical activity at level of ability
  • Commitment to continue lifestyle modifications while on Wegovy
  • Optimized on standard of care treatment for prevention of secondary cardiovascular events per prescriber (may include lipid-lowering, blood pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
  • No diagnosis of diabetes mellitus
  • No diagnosis of end-stage renal disease
  • No NYHA Class IV heart failure symptoms
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with any weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

  • Baseline BMI documentation (≥27 kg/m²)
  • Progress notes demonstrating established CVD (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease)
  • Prescriber attestation that Wegovy is prescribed by or in consultation with a cardiologist or neurologist
  • Documentation that patient is currently a non-smoker (not smoked in past 6 months)
  • Documentation that patient is partaking in a heart healthy diet
  • Documentation that patient is engaging in physical activity at their level of ability
  • Documentation of patient commitment to continue lifestyle modifications while on Wegovy
  • Documentation that patient is optimized on standard of care for secondary CVD prevention (lipid-lowering, blood-pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
  • Documentation that patient has no diagnosis of diabetes mellitus, ESRD, or NYHA Class IV heart failure
  • At recertification: documentation of ≥80% PDC since last approval
  • At recertification: documentation of continued non-smoker status, heart-healthy diet, and physical activity

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg — 4 pens per 28 days (Wegovy HD 7.2mg NOT approved for CV risk reduction indication); Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for Upon recertification: patient must be utilizing 2.4mg OR 1.7mg injection OR 25mg tablet as maintenance dose; must demonstrate ≥80% PDC (Percent Days Covered) since last approval; must still be a non-smoker, partaking in a heart healthy diet and engaging in physical activity; must not have developed type 2 diabetes, ESRD, or NYHA Class IV heart failure symptoms. Note: GDMT optimization and CVD diagnosis are not explicitly re-verified at continuation per policy text, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Diabetes mellitus diagnosis excludes from this indication (consider GLP-1 agonists FDA-approved for CV risk reduction in T2DM instead)
  • End-stage renal disease diagnosis excludes from this indication
  • NYHA Class IV heart failure symptoms exclude from this indication
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any weight loss drugs (Rx, OTC, or herbal) not approved
  • Wegovy HD 7.2mg not approved for this indication

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: Standards of care for secondary CVD prevention may include lipid-lowering therapies, blood pressure-lowering therapy, SGLT2 inhibitors when appropriate, and antiplatelet therapy when appropriate — prescriber determines optimization. Wegovy HD 7.2mg explicitly NOT approved for this indication. For patients with type 2 diabetes seeking CV risk reduction, policy directs to GLP-1 agonists FDA-approved for MACE reduction in T2DM. BMI thresholds may be adjusted for Asian population (≥25 kg/m² suggests clinical obesity) on case-by-case basis. Annual GLP-1 day-supply limits apply cumulatively across all products.

verified June 5, 2026 · source: weight-management-policy-pdf

Wegovy for Liver Disease (MASH)

What Excellus BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 35 or higher
  • BMI of 25 or higher for patients of Asian descent
  • 3 months of a documented diet and exercise program
  • Confirmed MASH diagnosis, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with moderate-to-advanced fibrosis — BMI ≥35 with MAFLD/MASH comorbidity

All of:

  • Age ≥ 18 years
  • Noncirrhotic MASH with moderate to advanced liver fibrosis (F2–F3 fibrosis)
  • BMI ≥ 35 kg/m² with qualifying comorbidity (MAFLD/MASH qualifies)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

  • Baseline BMI documentation (≥35 kg/m²)
  • Documentation of noncirrhotic MASH with F2–F3 fibrosis
  • Documentation of MAFLD/MASH as qualifying comorbidity
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg (Wegovy HD) — 4 pens per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days; first 6 fills for new starts limited to 30-day supply or less (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation criteria follow existing weight management policy: ≥5% weight loss by 7 months, maintained ≥5% weight loss or continued weight loss at subsequent recertifications, BMI not less than 18.5 kg/m², and maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). MASH fibrosis staging not re-verified at continuation per policy structure, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • BMI < 35 kg/m² considered not medically necessary for MASH even in presence of MAFLD/MASH — insufficient evidence of efficacy in non-obese/overweight population
  • Cirrhotic MASH not covered (noncirrhotic only)
  • Combination with other GIP and/or GLP-1 receptor agonists not approved
  • Combination with other weight loss drugs (Rx, OTC, or herbal) not approved
  • MASH indication approved under FDA accelerated approval — continued approval contingent upon verification of clinical benefit in confirmatory trial

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: FDA approved Wegovy injection for noncirrhotic MASH with moderate to advanced fibrosis (F2–F3) on August 15, 2025, under accelerated approval. Policy restricts coverage to patients with BMI ≥35 kg/m² by integrating MASH into existing weight management criteria (Class II obesity with MAFLD/MASH comorbidity). Policy explicitly states BMI <35 is not medically necessary citing: <3% of ESSENCE trial participants had BMI <27, mean trial BMI was 34.6, subgroup efficacy in non-obese/overweight not established, primary outcomes were biopsy-confirmed (not hard outcomes), long-term outcomes data expected 2029, and histologic improvements strongly correlate with weight reduction. No specific MASH confirmation method (FIB-4, FibroScan, biopsy, MRE, ELF) is specified in this policy — policy references FDA approval criteria of F2–F3 fibrosis only.

verified June 5, 2026 · source: weight-management-policy-pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 35 or higher
  • BMI of 25 or higher for patients of Asian descent
  • 3 months of a documented diet and exercise program
  • Confirmed MASH diagnosis, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with moderate-to-advanced fibrosis — BMI ≥35 with MAFLD/MASH comorbidity

All of:

  • Age ≥ 18 years
  • Noncirrhotic MASH with moderate to advanced liver fibrosis (F2–F3 fibrosis)
  • BMI ≥ 35 kg/m² with qualifying comorbidity (MAFLD/MASH qualifies)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

  • Baseline BMI documentation (≥35 kg/m²)
  • Documentation of noncirrhotic MASH with F2–F3 fibrosis
  • Documentation of MAFLD/MASH as qualifying comorbidity
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg (Wegovy HD) — 4 pens per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days; first 6 fills for new starts limited to 30-day supply or less (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation criteria follow existing weight management policy: ≥5% weight loss by 7 months, maintained ≥5% weight loss or continued weight loss at subsequent recertifications, BMI not less than 18.5 kg/m², and maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). MASH fibrosis staging not re-verified at continuation per policy structure, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • BMI < 35 kg/m² considered not medically necessary for MASH even in presence of MAFLD/MASH — insufficient evidence of efficacy in non-obese/overweight population
  • Cirrhotic MASH not covered (noncirrhotic only)
  • Combination with other GIP and/or GLP-1 receptor agonists not approved
  • Combination with other weight loss drugs (Rx, OTC, or herbal) not approved
  • MASH indication approved under FDA accelerated approval — continued approval contingent upon verification of clinical benefit in confirmatory trial

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: FDA approved Wegovy injection for noncirrhotic MASH with moderate to advanced fibrosis (F2–F3) on August 15, 2025, under accelerated approval. Policy restricts coverage to patients with BMI ≥35 kg/m² by integrating MASH into existing weight management criteria (Class II obesity with MAFLD/MASH comorbidity). Policy explicitly states BMI <35 is not medically necessary citing: <3% of ESSENCE trial participants had BMI <27, mean trial BMI was 34.6, subgroup efficacy in non-obese/overweight not established, primary outcomes were biopsy-confirmed (not hard outcomes), long-term outcomes data expected 2029, and histologic improvements strongly correlate with weight reduction. No specific MASH confirmation method (FIB-4, FibroScan, biopsy, MRE, ELF) is specified in this policy — policy references FDA approval criteria of F2–F3 fibrosis only.

verified June 5, 2026 · source: weight-management-policy-pdf

Why Wegovy requests get denied by Excellus BCBS

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Required prior medication trials not documented.
  6. Prescriber isn't the specialist the plan requires.
  7. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Excellus BCBS cover Wegovy?
Excellus BCBS covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Wegovy under Excellus BCBS?
For weight loss on Employer / Commercial Insurance plans, Excellus BCBS requires a BMI of 40 or higher, or 35 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Wegovy approval last with Excellus BCBS?
Initial approvals last 7 months, and renewals are granted in 6-month periods.
What does Excellus BCBS require to renew Wegovy?
At least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). Continued comprehensive weight management program enrollment required (provider acknowledgement via PA form or progress note). Wegovy HD 7.2mg only for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg.
How current is this information?
This page reflects Excellus BCBS's written policy as of its current version, last verified against the source document on June 5, 2026.

Other medications under Excellus BCBS

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Excellus BCBS's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.